President Donald Trump and Japanese Prime Minister Sanae Takaichi met Thursday in the Oval Office, where they discussed security, economic ties, and issues related to drug pricing reforms. The March 24 meeting included new commitments such as Japan's pledge to help secure shipping lanes in the Middle East and a $40 billion investment in American nuclear energy projects.
Drug pricing has become an important topic for both countries. For decades, Japan’s national health insurance system has set low reimbursement rates for new medicines and repeatedly reduced these prices over time. The latest revisions are set to cut reimbursements on various therapies beginning in April, aiming for a 4% reduction in total drug spending.
These price controls have been credited with restraining short-term spending but have also discouraged investment in research and development within Japan’s pharmaceutical sector. The global share of new medicines invented by Japanese companies dropped from 29% in the 1980s to just 7% by the 2010s. In addition, venture capital investment in Japan's biotech sector remains significantly lower compared to that of the United States.
Despite policy challenges, some investor interest remains. AN Venture Partners recently raised a $200 million fund to commercialize discoveries from Japanese laboratories, while Fast Track Initiative launched a $130 million life sciences fund aimed at building new biotech companies.
The article argues that reforming Japan’s drug pricing system could benefit patients who currently face long waits for access to innovative treatments approved elsewhere. "If Japan paid U.S. market prices for innovative drugs, biotech companies here in America, as well as in Japan and Europe, would collectively earn tens of billions in additional revenue," it says. This additional funding could support further research leading to more new medicines each year.
As discussions continue following the summit meeting between Trump and Takaichi, cooperation on drug pricing reforms is seen as an opportunity with potential benefits for both nations’ healthcare sectors.
